Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1991 Jul 1;174(1):151–160. doi: 10.1084/jem.174.1.151

The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies

PMCID: PMC2118886  PMID: 1676047

Abstract

Cryptococcus neoformans is a ubiquitous fungus that can cause serious infections in humans. The fungus has a polysaccharide (C. neoformans capsular polysaccharide; CNPS) capsule that contributes to its pathogenicity and can elicit an antibody response. Nevertheless, only 4 of 60 BALB/c mice chronically infected with C. neoformans had a detectable increase in serum anti-CNPS. The sera of three responder mice contained both IgM and IgG anti-CNPS antibody, and the titers of lambda and kappa anti-CNPS antibody were approximately equal. Eight IgM and one IgG3 monoclonal antibodies (mAbs) were generated from the spleen of one responder mouse, and one IgA was generated from the spleen of another mouse. Seven of the IgMs, the IgG3, and the IgA mAb had lambda light chains and were specific for serotype D CNPS. Molecular analysis confirmed that this was a highly restricted antibody response. All of the D-specific antibodies used VH441, JH3, and either V lambda 2/J lambda 2 or V lambda 1/J lambda 1, and all had the same heavy chain CDR3 amino acid sequence, even though there were differences in the nucleotide sequence of the N/D segment. One IgM mAb reacted with both serotype A and D CNPS, and this mAb used different VH and JH genetic elements and had kappa light chains. All the anti-CNPS mAbs used J proximal VH gene elements that have previously been shown to bind dextran and other polysaccharides. Sequence and Southern blot analysis indicate that the serotype-D CNPS-specific mAbs arose from only a few precursor B cells.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams D. I., Kuno S., Wong R., Jeffords K., Nash M., Molaghan J. B., Gorter R., Ueno R. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med. 1989 Feb 1;110(3):183–188. doi: 10.7326/0003-4819-110-3-183. [DOI] [PubMed] [Google Scholar]
  2. Akolkar P. N., Sikder S. K., Bhattacharya S. B., Liao J., Gruezo F., Morrison S. L., Kabat E. A. Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans. J Immunol. 1987 Jun 15;138(12):4472–4479. [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L., Edwards M. S., Schiffman G. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med. 1980 Jul 24;303(4):173–178. doi: 10.1056/NEJM198007243030401. [DOI] [PubMed] [Google Scholar]
  4. Baker P. J. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect Immun. 1990 Nov;58(11):3465–3468. doi: 10.1128/iai.58.11.3465-3468.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhattacharjee A. K., Bennett J. E., Glaudemans C. P. Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis. 1984 Sep-Oct;6(5):619–624. doi: 10.1093/clinids/6.5.619. [DOI] [PubMed] [Google Scholar]
  6. Borden P., Kabat E. A. Nucleotide sequence of the cDNAs encoding the variable region heavy and light chains of a myeloma protein specific for the terminal nonreducing end of alpha(1----6)dextran. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2440–2443. doi: 10.1073/pnas.84.8.2440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Caton A. J. A single pre-B cell can give rise to antigen-specific B cells that utilize distinct immunoglobulin gene rearrangements. J Exp Med. 1990 Sep 1;172(3):815–825. doi: 10.1084/jem.172.3.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Diamond R. D., Allison A. C. Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect Immun. 1976 Sep;14(3):716–720. doi: 10.1128/iai.14.3.716-720.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Diamond R. D. Antibody-dependent killing of Cryptococcus neopormans by human peripheral blood mononuclear cells. Nature. 1974 Jan 18;247(5437):148–150. doi: 10.1038/247148a0. [DOI] [PubMed] [Google Scholar]
  10. Diamond R. D., Bennett J. E. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974 Feb;80(2):176–181. doi: 10.7326/0003-4819-80-2-176. [DOI] [PubMed] [Google Scholar]
  11. Dromer F., Aucouturier P., Clauvel J. P., Saimot G., Yeni P. Cryptococcus neoformans antibody levels in patients with AIDS. Scand J Infect Dis. 1988;20(3):283–285. doi: 10.3109/00365548809032452. [DOI] [PubMed] [Google Scholar]
  12. Dromer F., Charreire J., Contrepois A., Carbon C., Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 1987 Mar;55(3):749–752. doi: 10.1128/iai.55.3.749-752.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dromer F., Salamero J., Contrepois A., Carbon C., Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun. 1987 Mar;55(3):742–748. doi: 10.1128/iai.55.3.742-748.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dromer F., Yeni P., Charreire J. Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics. 1988;28(6):417–424. doi: 10.1007/BF00355373. [DOI] [PubMed] [Google Scholar]
  15. Eckert T. F., Kozel T. R. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun. 1987 Aug;55(8):1895–1899. doi: 10.1128/iai.55.8.1895-1899.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. French D. L., Laskov R., Scharff M. D. The role of somatic hypermutation in the generation of antibody diversity. Science. 1989 Jun 9;244(4909):1152–1157. doi: 10.1126/science.2658060. [DOI] [PubMed] [Google Scholar]
  17. Goren M. B. Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J Immunol. 1967 May;98(5):914–922. [PubMed] [Google Scholar]
  18. Greenspan N. S., Dacek D. A., Cooper L. J. Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. I. The effect of temperature. J Immunol. 1988 Dec 15;141(12):4276–4282. [PubMed] [Google Scholar]
  19. Hartman A. B., Rudikoff S. VH genes encoding the immune response to beta-(1,6)-galactan: somatic mutation in IgM molecules. EMBO J. 1984 Dec 1;3(12):3023–3030. doi: 10.1002/j.1460-2075.1984.tb02249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ikeda R., Shinoda T., Fukazawa Y., Kaufman L. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol. 1982 Jul;16(1):22–29. doi: 10.1128/jcm.16.1.22-29.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Insel R. A., Anderson P. W. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J Exp Med. 1986 Feb 1;163(2):262–269. doi: 10.1084/jem.163.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kimura H., Buescher E. S., Ball E. D., Marcus D. M. Restricted usage of VH and V kappa genes by murine monoclonal antibodies against 3-fucosyllactosamine. Eur J Immunol. 1989 Sep;19(9):1741–1746. doi: 10.1002/eji.1830190932. [DOI] [PubMed] [Google Scholar]
  23. Kimura H., Cook R., Meek K., Umeda M., Ball E., Capra J. D., Marcus D. M. Sequences of the VH and VL regions of murine monoclonal antibodies against 3-fucosyllactosamine. J Immunol. 1988 Feb 15;140(4):1212–1217. [PubMed] [Google Scholar]
  24. Kozel T. R., Cazin J. Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun. 1971 Feb;3(2):287–294. doi: 10.1128/iai.3.2.287-294.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kozel T. R., Gotschlich E. C. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol. 1982 Oct;129(4):1675–1680. [PubMed] [Google Scholar]
  26. Kozel T. R., McGaw T. G. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect Immun. 1979 Jul;25(1):255–261. doi: 10.1128/iai.25.1.255-261.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lim T. S., Murphy J. W., Cauley L. K. Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in mice. Infect Immun. 1980 Aug;29(2):633–641. doi: 10.1128/iai.29.2.633-641.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lutz C. T., Bartholow T. L., Greenspan N. S., Fulton R. J., Monafo W. J., Perlmutter R. M., Huang H. V., Davie J. M. Molecular dissection of the murine antibody response to streptococcal group A carbohydrate. J Exp Med. 1987 Feb 1;165(2):531–545. doi: 10.1084/jem.165.2.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Monga D. P., Kumar R., Mohapatra L. N., Malaviya A. N. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect Immun. 1979 Oct;26(1):1–3. doi: 10.1128/iai.26.1.1-3.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Murphy J. W., Cox R. A. Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen. Clin Exp Immunol. 1988 Aug;73(2):174–180. [PMC free article] [PubMed] [Google Scholar]
  31. Murphy J. W., Cozad G. C. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun. 1972 Jun;5(6):896–901. doi: 10.1128/iai.5.6.896-901.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Nabavi N., Murphy J. W. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun. 1986 Feb;51(2):556–562. doi: 10.1128/iai.51.2.556-562.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nahmias C., Strosberg A. D., Emorine L. J. The immune response toward beta-adrenergic ligands and their receptors. VIII. Extensive diversity of VH and VL genes encoding anti-alprenolol antibodies. J Immunol. 1988 Feb 15;140(4):1304–1311. [PubMed] [Google Scholar]
  34. Nieto A., Gaya A., Jansa M., Moreno C., Vives J. Direct measurement of antibody affinity distribution by hapten-inhibition enzyme immunoassay. Mol Immunol. 1984 Jun;21(6):537–543. doi: 10.1016/0161-5890(84)90070-1. [DOI] [PubMed] [Google Scholar]
  35. Pollock R. R., French D. L., Metlay J. P., Birshtein B. K., Scharff M. D. Intravascular metabolism of normal and mutant mouse immunoglobulin molecules. Eur J Immunol. 1990 Sep;20(9):2021–2027. doi: 10.1002/eji.1830200921. [DOI] [PubMed] [Google Scholar]
  36. Rinaldi M. G., Drutz D. J., Howell A., Sande M. A., Wofsy C. B., Hadley W. K. Serotypes of Cryptococcus neoformans in patients with AIDS. J Infect Dis. 1986 Mar;153(3):642–642. doi: 10.1093/infdis/153.3.642. [DOI] [PubMed] [Google Scholar]
  37. Sanford J. E., Lupan D. M., Schlageter A. M., Kozel T. R. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun. 1990 Jun;58(6):1919–1923. doi: 10.1128/iai.58.6.1919-1923.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Spira G., Aguila H. L., Scharff M. D. T15 PC-binding monoclonal antibodies retain specificity when they switch from IgM to IgG. J Immunol. 1988 Apr 15;140(8):2675–2680. [PubMed] [Google Scholar]
  39. Tittle T. V., Rittenberg M. B. IgG B memory cell subpopulations: differences in susceptibility to stimulation by TI-1 and TI-2 antigens. J Immunol. 1980 Jan;124(1):202–206. [PubMed] [Google Scholar]
  40. Todaro-Luck F., Reiss E., Cherniak R., Kaufman L. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect Immun. 1989 Dec;57(12):3882–3887. doi: 10.1128/iai.57.12.3882-3887.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wallick S. C., Kabat E. A., Morrison S. L. Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen. J Exp Med. 1988 Sep 1;168(3):1099–1109. doi: 10.1084/jem.168.3.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wilson D. E., Bennett J. E., Bailey J. W. Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med. 1968 Mar;127(3):820–823. doi: 10.3181/00379727-127-32812. [DOI] [PubMed] [Google Scholar]
  43. Yancopoulos G. D., Alt F. W. Regulation of the assembly and expression of variable-region genes. Annu Rev Immunol. 1986;4:339–368. doi: 10.1146/annurev.iy.04.040186.002011. [DOI] [PubMed] [Google Scholar]
  44. Zuger A., Louie E., Holzman R. S., Simberkoff M. S., Rahal J. J. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986 Feb;104(2):234–240. doi: 10.7326/0003-4819-104-2-234. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES